|Bid||0.00 x 1200|
|Ask||0.00 x 1300|
|Day's Range||238.02 - 239.97|
|52 Week Range||163.08 - 247.64|
|Beta (5Y Monthly)||0.77|
|PE Ratio (TTM)||65.52|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Edwards Lifesciences (EW) closed the most recent trading day at $231.46, moving -0.67% from the previous trading session.
Boosted by average EPS growth of 84% over the last three quarters, life sciences leader and biologic drugmaker Repligen is now testing a new buy point.
In 2000 Mike Mussallem was appointed CEO of Edwards Lifesciences Corporation (NYSE:EW). This analysis aims first to...
Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57%. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. That's why we weren't […]
Dow futures: Will a not-so-forceful Star Wars lift or sink Disney stock? Also, Applied Materials, KLA, Inphi, Keysight Technologies and Edwards Lifesciences have new buy points.
The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals
Some stock market bears have been waiting for a US recession for four years. Is 2020 the year they will finally be right or will they have to throw in the towel and join the bull's party?
Edwards Lifesciences (EW) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
Edwards Lifesciences uses special equipment catered to fighting heart disease while also focusing on stakeholder capitalism. This enables Edwards Lifesciences to thrive financially and benefit a wider community beyond shareholders. Yahoo Finance’s Adam Shapiro and Julie Hyman discuss with Edwards Lifesciences CEO Mike Mussallem, KPMG Chief Economist Constance Hunter and Just Capital CEO Martin Whittaker on On the Move.